Alnylam Announces Preliminary Fourth Quarter and Full Year 2024 Global Net Product Revenues
Alnylam Pharmaceuticals, Inc. has reported a significant 33% annual growth in net product revenues for 2024, totaling $1,646 million from its products ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. The company has set an ambitious combined net product revenue guidance for 2025, aiming for between $2,050 million to $2,250 million, which positions Alnylam to achieve its goal of non-GAAP profitability.
2025 Combined Net Product Revenue & Non-GAAP Operating Income Guidance
For 2025, Alnylam anticipates combined net product revenues for its TTR franchise (ONPATTRO and AMVUTTRA) to be between $1,600 million to $1,725 million, representing a 36% growth at the mid-point of the guidance range compared to 2024. The Rare franchise (GIVLAARI and OXLUMO) is expected to generate between $450 million to $525 million, a 15% growth at the mid-point.
2025 Product and Pipeline Goals
Alnylam's pipeline goals for 2025 include achieving FDA approval for vutrisiran in treating ATTR amyloidosis with cardiomyopathy by March 23, 2025, and securing additional global approvals in Japan and the EU. The company also plans to initiate a Phase 3 study for nucresiran in patients with ATTR amyloidosis with cardiomyopathy and report results from the KARDIA-3 Phase 2 study for zilebesiran. Additionally, Alnylam expects to initiate a Phase 2 study in Alzheimer’s disease for mivelsiran and a Phase 2 study in a bleeding disorder for ALN-6400.
Partner-Led Program Highlights
Alnylam's partnered programs, including fitusiran with Sanofi and elebsiran with Vir Biotechnology, are progressing, with expectations for FDA approval and initiating Phase 3 studies, respectively.
Alnylam's achievements in 2024 and its ambitious goals for 2025 underscore its commitment to delivering transformative medicines and achieving sustainable growth in the biotech industry.
